SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

June 18, 2024

https://www.globenewswire.com/news-release/2024/06/18/2900714/0/en/SAB-Biotherapeutics-to-Present-at-the-American-Diabetes-Association-84th-Scientific-Sessions.html

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq:SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida. The poster will be presented by SAB’s Senior Program Manager, Eric Sandhurst, Ph.D, and published online in the journal Diabetes®.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.